Research programme: monoclonal antibody therapeutics - Arrowhead Pharmaceuticals/Juno Therapeutics

Drug Profile

Research programme: monoclonal antibody therapeutics - Arrowhead Pharmaceuticals/Juno Therapeutics

Alternative Names: Antibody cancer therapeutics - Arrowhead Pharmaceuticals/Juno Therapeutics; Human antibody therapeutic candidates - Arrowhead Pharmaceuticals/Juno Therapeutics

Latest Information Update: 09 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mercator Therapeutics; X-BODY BioSciences
  • Developer Alvos Therapeutics; Juno Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 02 Jun 2015 X-BODY BioSciences has been acquired by Juno Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top